Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00279045
Status:
COMPLETED
Last Update Posted:
2017-11-29
First Post:
2006-01-17
Brief Title:
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or GlyburideGlibenclamide
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or GlyburideGlibenclamide in Patients With Drug-Naive Recently Diagnosed Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2017-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone metformin and glyburideglibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None